CAR Treg has also shown potential in preclinical studies and early clinical trials for a variety of autoimmune diseases, including graft-versus-host disease, type 1 diabetes, multiple sclerosis, etc. For instance, in immunodeficient mice that were reconstituted with human PBMCs, anti-CD19 CAR Tregs inhibited the generation of antibodies, lowering the likelihood of graft-versus-host disease [125]. The gene discussed is CD19; the disease is graft versus host disease.